@article{oai:nagoya.repo.nii.ac.jp:00024846,
 author = {Masahiro, Shibata and Mitsuro, Kanda and Haruyoshi, Tanaka and Shinichi, Umeda and Takashi, Miwa and Dai, Shimizu and Masamichi, Hayashi and Takahiro, Inaishi and Noriyuki, Miyajima and Yayoi, Adachi and Yuko, Takano and Kenichi, Nakanishi and Dai, Takeuchi and Sumiyo, Noda and Yasuhiro, Kodera and Toyone, Kikumori},
 issue = {3},
 journal = {Oncology Reports},
 month = {Jul},
 note = {Breast cancer (BC) is the most common malignant tumor among women worldwide. Development of novel molecular targets is important to improve prognosis of BC patients. Derlin 3 (DERL3) gene is a member of derlin family, and its coding protein is critical to the endoplasmic reticulum-associated degradation mechanism. However, its oncological role in breast cancer remains unclear. This study evaluated DERL3 expression and function in BC. We analyzed DERL3 mRNA in 13 BC and two non-cancerous cell lines, and explored effects of DERL3 knockdown on BC proliferation, invasion and migration. We also evaluated correlation of DERL3 mRNA expression levels with clinicopathological factors and prognosis in 167 BC patients. DERL3 mRNA expression was detected in five (38%) BC cell lines. Inhibiting DERL3 expression significantly decreased proliferation and invasion in BC cells. Specimens from patients with lymph node metastasis had higher DERL3 mRNA expression than those without (P=0.030). Patients in the highest quartile for DERL3 mRNA expression (n=42) were more likely to experience shorter overall survival than other patients (P=0.032). These findings indicate that DERL3 promotes malignant phenotype in BC cells. DERL3 may serve as a potential prognostic marker and therapeutic target for BC.},
 pages = {1760--1766},
 title = {Overexpression of Derlin 3 is associated with malignant phenotype of breast cancer cells},
 volume = {38},
 year = {2017}
}